GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ASP 3026 | ASP3026
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: ASP-3026 is a second generation ALK inhibitor designed to target ALK rearrangements which are the oncogenic drivers of some non-small cell lung cancers (NSCLCs) and T-cell lymphomas known as ALK- expressing anaplastic large-cell lymphoma (ALK+ALCL) .
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| ASP-3026 is effective against NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in vivo [1]. It also effective against tumour cells expressing the EML4-ALK rearrangement, even when possessing a crizotinib-resistance-conferring gatekeeper mutation (L1196M) [2] (in vivo and in vitro results). We have been unable to find affinity data for ASP-3026 using recombinant ALK protein.  |